Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: Emerging preclinical and clinical evidence

Therapeutic Advances in Hematology

Volumn 6, Issue 3, 2015, Pages 128-141

  Chaidos, Aristeidis ^a   Caputo, Valentina ^a   Karadimitris, Anastasios ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

acetylation; acute leukaemia; benzodiazepines; BET proteins; bromodomains; lymphoma; multiple myeloma; MYC

Indexed keywords

EID: 84993709912     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620715576662     Document Type: Review

References (111)

1. Adachi K. Hikawa H. Hamada M. Endoh J. Ishibuchi S. Fujie N. et al. (2011) Thienotriazolodiazepine Compound and Medicinal Use Thereof. Mitsubishi Tanabe Pharma Corporation, Osaka-shi, Japan.
2. Allfrey V. Faulkner R. Mirsky A. (1964) Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc Natl Acad Sci USA 51: 786–794.
3. Asangani I. Dommeti V. Wang X. Malik R. Cieslik M. Yang R. et al. (2014) Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 510: 278–282.
4. Bartholomeeusen K. Xiang Y. Fujinaga K. Peterlin B. (2012) Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-Tefb) from 7SK small nuclear ribonucleoprotein. J Biol Chem 287: 36609–36616.
5. Beguelin W. Popovic R. Teater M. Jiang Y. Bunting K. Rosen M. et al. (2013) EZH 2 is required for germinal center formation and somatic EZH 2 mutations promote lymphoid transformation. Cancer Cell 23: 677–692.
6. Bhadury J. Nilsson L. Muralidharan S. Green L. Li Z. Gesner E. et al. (2014) BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. Proc Natl Acad Sci USA 111 (26): E2721–E2730.
7. Boi M. Bonetti P. Ponzoni M. Tibiletti M. Stathis A. Cvitkovic E. et al. (2012) The Brd-inhibitor OTX 015 shows pre-clinical activity in anaplastic large T-cell lymphoma (ALCL). Blood 120: 4872
8. Bonetti P. Boi M. Ponzoni M. Tibiletti M. Stahis A. Inghirami G. et al. (2012 a) The Brd-inhibitor OTX 015 is active in pre-clinical models of mature B-cell lymphoid tumors. Blood 120 (21): 1657.
9. Bonetti P. Ponzoni M. Tibiletti M. Stathis A. Heirat P. Zucca E. et al. (2012 b) The BRD-inhibitor OTX 015 shows pre-clinical activity in diffuse large B-cell lymphoma (DLBCL). Eur J Cancer 48: 163.
10. Borah J. Mujtaba S. Karakikes I. Zeng L. Muller M. Patel J. et al. (2011) A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes. Chem Biol 18: 531–541.
11. Borggrefe T. Yue X. (2011) Interactions between subunits of the mediator complex with gene-specific transcription factors. Semin Cell Dev Biol 22: 759–768.
12. Braun T. Coude M. Berrou J. Bertrand S. Riveiro E. Herait P. et al. (2013) Preclinical study of the bromodomain inhibitor OTX 015 in acute myeloid (AML) and lymphoid (ALL) leukemias. Blood 122 (21): 4218–4219.
13. Campbell R. Tummino P. (2014) Cancer epigenetics drug discovery and development: the challenge of hitting the mark. J Clin Invest 124: 64–69.
14. Campeau E. Jahagirdar R. Wu J. Gesner E.M. Kharenko O. Yu R. et al. (2013) RVX-2135 is a novel, orally bioavailable epigenetic BET inhibitor that synergizes with cytarabine and idarubicin to inhibit proliferation of acute myeloid leukemia cells. Cancer Res 73(8 supplement): LB–92.
15. Carro M. Lim W. Alvarez M. Bollo R. Zhao X. Snyder E. et al. (2010) The transcriptional network for mesenchymal transformation of brain tumours. Nature 463: 318–325.
16. Ceribelli M. Kelly P. Shaffer A. Wright G. Xiao W. Yang Y. et al. (2014) Blockade of oncogenic ikappab kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proc Natl Acad Sci USA 111: 11365–11370.
17. Chaidos A. Caputo V. Gouvedenou K. Liu B. Marigo I. Chaudhry M. et al. (2014) Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood 123: 697–705.
18. Chapuy B. McKeown M. Lin C. Monti S. Roemer M. Qi J. et al. (2013) Discovery and characterization of super-enhancer-associated dependencies in diffuse large B-cell lymphoma. Cancer Cell 24: 777–790.
19. Chen R. Yik J. Lew Q. Chao S. (2014) BRD 4 and HEXIM1: multiple roles in P-TEFb regulation and cancer. Biomed Res Int 2014: 232870.
20. Chesi M. Matthews G. Garbitt V. Palmer S. Shortt J. Lefebure M. et al. (2012) Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood 120: 376–385.
21. Coiffier B. Pro B. Prince H. Foss F. Sokol L. Greenwood M. et al. (2014) Romidepsin for the treatment of relapsed / refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol 7 (1): 11.
22. Conaway R. Conaway J. (2011) Function and regulation of the mediator complex. Curr Opin Genet Dev 21: 225–230.
23. Crawford N. Alsarraj J. Lukes L. Walker R. Officewala J. Yang H. et al. (2008) Bromodomain 4 activation predicts breast cancer survival. Proc Natl Acad Sci USA 105: 6380–6385.
24. Dawson M. Gudgin E. Horton S. Giotopoulos G. Meduri E. Robson S. et al. (2014) Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia. Leukemia 28: 311–320.
25. Dawson M. Prinjha R. Dittmann A. Giotopoulos G. Bantscheff M. Chan W. et al. (2011) Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478: 529–533.
26. Delmore J. Issa G. Lemieux M. Rahl P. Shi J. Jacobs H. et al. (2011) BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146: 904–917.
27. Dhalluin C. Carlson J. Zeng L. He C. Aggarwal A. Zhou M. (1999) Structure and ligand of a histone acetyltransferase bromodomain. Nature 399: 491–496.
28. Dimopoulos M. Siegel D. Lonial S. Qi J. Hajek R. Facon T. et al. (2013) Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol 14: 1129–1140.
29. Duvic M. Talpur R. Ni X. Zhang C. Hazarika P. Kelly C. et al. (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109: 31–39.
30. Figueroa M. Skrabanek L. Li Y. Jiemjit A. Fandy T. Paietta E. et al. (2009) MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 114: 3448–3458.
31. Filippakopoulos P. Knapp S. (2012) The bromodomain interaction module. FEBS Lett 586 (17): 2692–2704.
32. Filippakopoulos P. Picaud S. Fedorov O. Keller M. Wrobel M. Morgenstern O. et al. (2012 a) Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family. Bioorg Med Chem 20: 1878–1886.
33. Filippakopoulos P. Picaud S. Mangos M. Keates T. Lambert J. Barsyte-Lovejoy D. et al. (2012 b) Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 149: 214–231.
34. Filippakopoulos P. Qi J. Picaud S. Shen Y. Smith W. Fedorov O. et al. (2010) Selective inhibition of BET bromodomains. Nature 468: 1067–1073.
35. French C. Miyoshi I. Aster J. Kubonishi I. Kroll T. Dal Cin P. et al. (2001) BRD 4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19). Am J Pathol 159: 1987–1992.
36. French C. Miyoshi I. Kubonishi I. Grier H. Perez-Atayde A. Fletcher J. (2003) BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res 63: 304–307.
37. French C. Ramirez C. Kolmakova J. Hickman T. Cameron M. Thyne M. et al. (2008) BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Oncogene 27: 2237–2242.
38. Gautschi J. Minikis R. (2014) Pharmaceutical formulation containing thienotriazolodiazepine compounds. International Patent No. PCT/IB2013/003026 (WO/2014/068402).
39. Gilliland D. Jordan C. Felix C. (2004) The molecular basis of leukemia. Hematology Am Soc Hematol Educ Program 80–97.
40. Gosmini R. Nguyen V. Toum J. Simon C. Brusq J. Krysa G. et al. (2014) The discovery of I-BET726 (GSK1324726a), a potent tetrahydroquinoline apoa 1 up-regulator and selective BET bromodomain inhibitor. J Med Chem 57: 8111–8131.
41. Grant S. (2009) New agents for AML and MDS. Best Pract Res Clin Haematol 22: 501–507.
42. Grant S. Easley C. Kirkpatrick P. (2007) Vorinostat. Nat Rev Drug Discov 6: 21–22.
43. Greenwald R. Tumang J. Sinha A. Currier N. Cardiff R. Rothstein T. et al. (2004) E Mu-BRD2 transgenic mice develop B-cell lymphoma and leukemia. Blood 103: 1475–1484.
44. Griffiths E. Gore S. (2013) Epigenetic therapies in MDS and AML. Adv Exp Med Biol 754: 253–283.
45. Hargreaves D. Horng T. Medzhitov R. (2009) Control of inducible gene expression by signal-dependent transcriptional elongation. Cell 138: 129–145.
46. He N. Pezda A. Zhou Q. (2006) Modulation of a P-TEFb functional equilibrium for the global control of cell growth and differentiation. Mol Cell Biol 26: 7068–7076.
47. Herait P. Thieblemont C. Raffoux E. Magarotto V. Stathis A. Thomas X. et al. (2013) BET-bromodomain inhibitor OTX 015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies. In: 105th Annual Meeting of the American Association for Cancer Research (AACR), 5–9 April, San Diego, CA.
48. Hewings D. Wang M. Philpott M. Fedorov O. Uttarkar S. Filippakopoulos P. et al. (2011) 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands. J Med Chem 54: 6761–6770.
49. Heyn H. Esteller M. (2013) EZH2: an epigenetic gatekeeper promoting lymphomagenesis. Cancer Cell 23: 563–565.
50. Hnisz D. Abraham B. Lee T. Lau A. Saint-Andre V. Sigova A. et al. (2013) Super-enhancers in the control of cell identity and disease. Cell 155: 934–947.
51. Houzelstein D. Bullock S. Lynch D. Grigorieva E. Wilson V. Beddington R. (2002) Growth and early postimplantation defects in mice deficient for the bromodomain-containing protein BRD4. Mol Cell Biol 22: 3794–3802.
52. Huang H. Zhang J. Shen W. Wang X. Wu Jiawen Wu Jihui et al. (2007) Solution structure of the second bromodomain of BRD 2 and its specific interaction with acetylated histone tails. BMC Struct Biol 7: 57.
53. Jahagirdar R. Zhang H. Azhar S. Tobin J. Attwell S. Yu R. et al. (2014) A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice. Atherosclerosis 236: 91–100.
54. Jang M. Mochizuki K. Zhou M. Jeong H. Brady J. Ozato K. (2005) The bromodomain protein BRD 4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol Cell 19: 523–534.
55. Jiang Y. Dunbar A. Gondek L. Mohan S. Rataul M. O'Keefe C. et al. (2009) Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 113: 1315–1325.
56. Kanno T. Kanno Y. Siegel R. Jang M. Lenardo M. Ozato K. (2004) Selective recognition of acetylated histones by bromodomain proteins visualized in living cells. Mol Cell 13: 33–43.
57. Keilhack H. (2013) Preclinical characterization of E7438, a potent, selective EZH 2 inhibitor with robust antitumor activity against EZH 2 mutated NHL xenografts in mice. Ann Oncol 24: 13.
58. King B. Trimarchi T. Reavie L. Xu L. Mullenders J. Ntziachristos P. et al. (2013) The ubiquitin ligase FBXW 7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell 153: 1552–1566.
59. Kouzarides T. (2007) Chromatin modifications and their function. Cell 128: 693–705.
60. Krivtsov A. Armstrong S. (2007) MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 7: 823–833.
61. Leroy G. Rickards B. Flint S. (2008) The double bromodomain proteins BRD 2 and BRD 3 couple histone acetylation to transcription. Mol Cell 30: 51–60.
62. Ley T. Ding L. Walter M. Mclellan M. Lamprecht T. Larson D. et al. (2010) DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363: 2424–2433.
63. Lin C. Smith E. Takahashi H. Lai K. Martin-Brown S. Florens L. et al. (2010) AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Molecular Cell 37: 429–437.
64. Liu L. Xu Y. He M. Zhang M. Cui F. Lu L. et al. (2014) Transcriptional pause release is a rate-limiting step for somatic cell reprogramming. Cell Stem Cell 15: 574–588.
65. Loven J. Hoke H. Lin C. Lau A. Orlando D. Vakoc C. et al. (2013) Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153: 320–334.
66. Mann B. Johnson J. Cohen M. Justice R. Pazdur R. (2007) FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12: 1247–1252.
67. Mccabe M. Ott H. Ganji G. Korenchuk S. Thompson C. van Aller G. et al. (2012) EZH 2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492: 108–112.
68. Mertz J. Conery A. Bryant B. Sandy P. Balasubramanian S. Mele D. et al. (2011) Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci USA 108: 16669–16674.
69. Mirguet O. Gosmini R. Toum J. Clement C. Barnathan M. Brusq J. et al. (2013) Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains. J Med Chem 56: 7501–7515.
70. Mirguet O. Lamotte Y. Donche F. Toum J. Gellibert F. Bouillot A. et al. (2012) From ApoA 1 upregulation to BET family bromodomain inhibition: discovery of I-BET151. Bioorg Med Chem Lett 22: 2963–2967.
71. Miyoshi S. Ooike S. Iwata K. Hikawa H. Sugahara K. (2009) Antitumor agent. International Patent No. PCT/JP2008/073864 (WO/2009/084693).
72. Miyoshi S. Ooike S. Iwata K. Hikawa H. Sugahara K. (2013) Antitumor Agent. Mitsubishi Tanabe Pharma Corporation, Osaka-shi, Japan.
73. Moros A. Rodriguez V. Saborit-Villarroya I. Montraveta A. Balsas P. Sandy P. et al. (2014) Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI 203 in bortezomib-resistant mantle cell lymphoma. Leukemia 28: 2049–2059.
74. Nicodeme E. Jeffrey K. Schaefer U. Beinke S. Dewell S. Chung C. et al. (2010) Suppression of inflammation by a synthetic histone mimic. Nature 468: 1119–1123.
75. Noel J. Iwata K. Ooike S. Sugahara K. Nakamura H. Daibata M. (2013) Development of the BET bromodomain inhibitor OTX015. Mol Cancer Ther 12: C244.
76. Ott C. Kopp N. Bird L. Paranal R. Qi J. Bowman T. et al. (2012) BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 120: 2843–2852.
77. Paoluzzi L. Segura M. Fontanals-Cirera B. Gaziel-Sovran A. Guijarro M. Hanniford D. et al. (2013) Targeting BET proteins in melanoma: a novel treatment approach. ASCO Meeting Abstracts 31: 9091.
78. Park-Min K. Lim E. Lee M. Park S. Giannopoulou E. Yarilina A. et al. (2014) Inhibition of osteoclastogenesis and inflammatory bone resorption by targeting BET proteins and epigenetic regulation. Nat Commun 5: 5418.
79. Perez-Galan P. Mora-Jensen H. Weniger M. Shaffer A. III Rizzatti E. Chapman C. et al. (2011) Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. Blood 117: 542–552.
80. Picaud S. Wells C. Felletar I. Brotherton D. Martin S. Savitsky P. et al. (2013) RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc Natl Acad Sci USA 110: 19754–19759.
81. Puissant A. Frumm S. Alexe G. Bassil C. Qi J. Chanthery Y. et al. (2013) Targeting mycn in neuroblastoma by BET bromodomain inhibition. Cancer Discov 3: 308–323.
82. Rahl P. Lin C. Seila A. Flynn R. Mccuine S. Burge C. et al. (2010) c-Myc regulates transcriptional pause release. Cell 141: 432–445.
83. Raj K. Mufti G. (2006) Azacytidine (Vidaza(R)) in the treatment of myelodysplastic syndromes. Ther Clin Risk Manag 2: 377–388.
84. Reynoird N. Schwartz B. Del Vecchio M. Sadoul K. Meyers D. Mukherjee C. et al. (2010) Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains. EMBO J 29: 2943–2952.
85. Roderick J. Tesell J. Shultz L. Brehm M. Greiner D. Harris M. et al. (2014) c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood 123: 1040–1050.
86. Sachchidanand, Resnick Silverman L., Yan S., Mutjaba S., Liu W., Zeng L., et al. (2006) Target structure-based discovery of small molecules that block human p 53 and CREB binding protein association. Chem Biol 13: 81–90.
87. Schroder S. Cho S. Zeng L. Zhang Q. Kaehlcke K. Mak L. et al. (2012) Two-pronged binding with bromodomain-containing protein 4 liberates positive transcription elongation factor b from inactive ribonucleoprotein complexes. J Biol Chem 287: 1090–1099.
88. Seal J. Lamotte Y. Donche F. Bouillot A. Mirguet O. Gellibert F. et al. (2012) Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A). Bioorg Med Chem Lett 22: 2968–2972.
89. Shaffer A. Emre N. Lamy L. Ngo V. Wright G. Xiao W. et al. (2008) IRF 4 addiction in multiple myeloma. Nature 454: 226–231.
90. Shahbazian M. Grunstein M. (2007) Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem 76: 75–100.
91. Silverman L. (2004) DNA methyltransferase inhibitors in myelodysplastic syndrome. Best Pract Res Clin Haematol 17: 585–594.
92. Silverman L. Mufti G. (2005) Methylation inhibitor therapy in the treatment of myelodysplastic syndrome. Nat Clin Pract Oncol 2(Suppl. 1): S12–S23.
93. Smith S. Sanchez R. Zhou M. (2014) Privileged diazepine compounds and their emergence as bromodomain inhibitors. Chem Biol 21: 573–583.
94. Straus D. Hamlin P. Matasar M. Lia Palomba M. Drullinsky P. Zelenetz A. et al. (2014) Phase I / II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation. Br J Haematol 168 (5): 663–670.
95. Straw R. (1985) Brief review of published alprazolam clinical studies. Br J Clin Pharmacol 19(Suppl. 1): 57S–59S.
96. Tolani B. Gopalakrishnan R. Punj V. Matta H. Chaudhary P. (2014) Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors. Oncogene 33: 2928–2937.
97. Treppendahl M. Kristensen L. Gronbaek K. (2014) Predicting response to epigenetic therapy. J Clin Invest 124: 47–55.
98. Wyce A. Degenhardt Y. Bai Y. Le B. Korenchuk S. Crouthame M. et al. (2013 a) Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer. Oncotarget 4: 2419–2429.
99. Wyce A. Ganji G. Smitheman K. Chung C. Korenchuk S. Bai Y. et al. (2013 b) BET inhibition silences expression of MYCN and BCL 2 and induces cytotoxicity in neuroblastoma tumor models. PloS ONE 8: e72967.
100. Wyspianska B. Bannister A. Barbieri I. Nangalia J. Godfrey A. Calero-Nieto F. et al. (2014) BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms. Leukemia 28: 88–97.
101. Yan J. Diaz J. Jiao J. Wang R. You J. (2011) Perturbation of BRD 4 protein function by BRD4-NUT protein abrogates cellular differentiation in NUT midline carcinoma. J Biol Chem 286: 27663–27675.
102. Yang Z. He N. Zhou Q. (2008) Brd 4 recruits P-TEFb to chromosomes at late mitosis to promote G 1 gene expression and cell cycle progression. Mol Cell Biol 28: 967–976.
103. Yang Z. Yik J. Chen R. He N. Jang M. Ozato K. et al. (2005) Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol Cell 19: 535–545.
104. Yap D. Chu J. Berg T. Schapira M. Cheng S. Moradian A. et al. (2011) Somatic mutations at EZH 2 Y641 act dominantly through a mechanism of selectively altered PRC 2 catalytic activity, to increase H3K27 trimethylation. Blood 117: 2451–2459.
105. Yashiro-Ohtani Y. Wang H. Zang C. Arnett K. Bailis W. Ho Y. et al. (2014) Long-range enhancer activity determines Myc sensitivity to Notch inhibitors in T cell leukemia. Proc Natl Acad Sci USA 111: E4946–E4953.
106. Yokoyama A. Lin M. Naresh A. Kitabayashi I. Cleary M. (2010) A higher-order complex containing AF 4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell 17: 198–212.
107. Zhang G. Liu R. Zhong Y. Plotnikov A. Zhang W. Zeng L. et al. (2012 a) Down-regulation of NF-kappab transcriptional activity in HIV-associated kidney disease by BRD 4 inhibition. J Biol Chem 287: 28840–28851.
108. Zhang X. Zhao X. Fiskus W. Lin J. Lwin T. Rao R. et al. (2012 b) Coordinated silencing of MYC-mediated MiR-29 by HDAC 3 and EZH 2 as a therapeutic target of histone modification in aggressive B-cell lymphomas. Cancer Cell 22: 506–523.
109. Zhao X. Lwin T. Zhang X. Huang A. Wang J. Marquez V. et al. (2013 a) Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity. Leukemia 27: 2341–2350.
110. Zhao Y. Yang C. Wang S. (2013 b) The making of I-BET762, a BET bromodomain inhibitor now in clinical development. J Med Chem 56: 7498–7500.
111. Zuber J. Shi J. Wang E. Rappaport A. Herrmann H. Sison E. et al. (2011) RNAi screen identifies BRD 4 as a therapeutic target in acute myeloid leukaemia. Nature 478: 524–528.